Breastfeeding moms with IBD: new study checks drug levels in milk
NCT ID NCT07612267
First seen May 28, 2026 · Last updated Jun 22, 2026 · Updated 5 times
Summary
This study will measure the amount of mirikizumab, a drug for inflammatory bowel disease, in the breast milk of 14 breastfeeding women who are already taking it. The goal is to see how much of the drug passes into milk, which can help guide safe use during breastfeeding. Participants will be followed for up to 94 days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aarhus Universitetshospital, Aarhus Sygehus
Aarhus N, 82000, Denmark
Contact
-
Chaim Sheba Medical Center
Ramat Gan, 52621, Israel
Contact
-
DC-MED Micha Kowalski S.K. - ul. Kilinskiego 6
Radom, 26-610, Poland
Contact
-
Digestive Disease Medicine of Central New York
Utica, New York, 13502, United States
Contact
-
Fondazione Policlinico Universitario A Gemelli - Rome - PPDS
Lazio, 00136, Italy
Contact
-
GI Research
Columbia, V6G 2Z6, Canada
Contact
-
Hospital Universitario La Paz
Madrid, 28046, Spain
Contact
-
Interdisziplinäres Crohn Colitis Centrum Rhein-Main
Frankfurt am Main, 60594, Germany
Contact
-
Johns Hopkins Bayview Medical Center
Baltimore, Maryland, 21224-2735, United States
Contact
-
Klinikum Ernst von Bergmann
Potsdam, D-14467, Germany
Contact
-
Northwest Gastroenterologist
Glenview, Illinois, 60026-8000, United States
Contact
-
Ospedale San Raffaele S.r.l. - PPDS
Lombardia, 20132, Italy
Contact
-
Ospedale Sandro Pertini
Roma, 00157, Italy
Contact
-
Ospedale di Rho - UOC Gastroenterologia
Rho, 20017, Italy
Contact
-
Rabin Medical Center - PPDS
HaMerkaz, Israel
Contact
-
Rigshospitalet
Copenhagen, 2100, Denmark
Contact
-
Shaare Zedek Medical Center
Jerusalem, 9013102, Israel
Contact
-
Slagelse Hospital
Slagelse, 4200, Denmark
Contact
-
Tel Aviv Sourasky Medical Center Ichilov - PPDS
Tel Aviv, 6423906, Israel
Contact
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
Contact
-
University of Iowa
Iowa City, Iowa, 52242, United States
Contact
-
WIP Warsaw IBD Point Profesor Kierkus
Warsaw, 04-501, Poland
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mirikizumab
What this could lead to
If successful, this study will help doctors understand whether mirikizumab passes into breast milk, guiding safer use during breastfeeding.
What could go wrong
This is a small, early-stage observational study with only 14 participants, so results may not apply to all women. It does not test treatment effectiveness.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.